Biomarkers Currently Tested in Metastatic NSCLC

In early-stage NSCLC, biomarker testing typically focuses on EGFR mutations, ALK rearrangements, and PD-L1 expression, largely to guide decisions around adjuvant targeted therapy or immunotherapy. While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as emerging data support targeted options in earlier disease settings. Expanding biomarker testing in early-stage NSCLC ensures that high-risk patients are identified sooner and may benefit from precision therapies that could reduce recurrence risk and improve long-term survival. Broader testing also helps align early-stage treatment strategies with the advances seen in metastatic disease, paving the way for more individualized and potentially more effective perioperative treatment plans.